🚨 Breaking News The U.S. FDA has approved acalabrutinib (CALQUENCE®) from @AstraZeneca in combination with venetoclax as the first all-oral, fixed-duration (14-month) regimen for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In the AMPLIFY clinical trial, 77% patients treated with acalabrutinib and venetoclax were progression-free at 3 years. These patients had a 35% reduction in the risk of disease progression or death. Read the full article here:https://healthtree.org/cll/community/articles/26-acalabrutinib-venetoclax-for-cll-sll?utm_source=social_media&utm_medium=meta&utm_campaign=socialmediaorganic&utm_content=general